Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON35820
NL-OMON35820
Completed
Not Applicable

A phase 1 study to investigate the absorption, metabolism and excretion of [14C] AT1001 (migalastat hydrochloride) following a single oral administration in healthy volunteers. - [14C]-AT1001 tracer label study

Amicus Therapeutics, Inc.0 sites6 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Amicus Therapeutics, Inc.
Enrollment
6
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Healthy male subjects, 30 \- 55 years, BMI of \*18\.0 to \*30\.0, no smoking.

Exclusion Criteria

  • •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Phase 1 study to investigate the absorption, metabolism and excretion of 14C-Orteronel (TAK-700) following a single oral administration in healthy subjectsProstate cancer10036958
NL-OMON36117Millenium Pharmaceuticals6
Completed
Not Applicable
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of 14C-PTC299 Following Multiple Oral Dose Administrations in Healthy Volunteers
NL-OMON50826PTC Therapeutics, Inc.7
Completed
Not Applicable
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of PTC857 Following Oral Administration of a Single Dose of 14C-PTC857 at Steady-State Conditions in Healthy Male Volunteers.
NL-OMON51552PTC Therapeutics, Inc.8
Completed
Not Applicable
A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of Radiolabeled [14C] R924548 Following Single Oral Dose Administration in Healthy Male Subjectsimmune-mediated diseasesrheuma10003816
NL-OMON37118Rigel Pharmaceuticals, Inc6
Completed
Phase 1
A study to see how [14C]-S-033188 is taken up, broken down and removed from the bodyInfluenza virus infectionRespiratoryInfluenza, virus not identified
ISRCTN74587134Shionogi Ltd6